ZBIO vs JNJ vs PFE vs CRL vs IQV vs JPM

For growth investors, Zenas BioPharma, Inc.

(ZBIO) is the stronger pick with 100. 0% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Zenas BioPharma, Inc. (ZBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Johnson & Johnson at 41. 6x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Johnson & Johnson's 37. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -47. 2% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ZBIO's +10. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

01β versus Charles River Laboratories International, Inc. 's 1. 39β — meaning CRL is approximately 18377% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Zenas BioPharma, Inc. (ZBIO) carries a lower debt/equity ratio of 33% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zenas BioPharma, Inc.

(ZBIO) is pulling ahead at 100. 0% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -37. 8% for Zenas BioPharma, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -21. 1% for ZBIO. At the gross margin level — before operating expenses — ZBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Johnson & Johnson's 37. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 20. 8x for Johnson & Johnson — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZBIO: 76. 8% to $35. 00.

In this comparison, PFE (6.

6% yield), JNJ (2. 0% yield), JPM (1. 9% yield) pay a dividend. ZBIO, CRL, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

01), 2. 0% yield, +142. 4% 10Y return). Both have compounded well over 10 years (JNJ: +142. 4%, ZBIO: +10. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZBIO (Healthcare) and JNJ (Healthcare) and PFE (Healthcare) and CRL (Healthcare) and IQV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZBIO is a small-cap high-growth stock; JNJ is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JNJ, PFE, JPM pay a dividend while ZBIO, CRL, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.